Xenon (XENE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-279.3M
Net Income
-234.3M
Balance Sheet Metrics
Total Assets
798.1M
Total Liabilities
43.2M
Shareholders Equity
754.9M
Debt to Equity
0.06
Cash Flow Metrics
Operating Cash Flow
-190.5M
Free Cash Flow
-184.5M
Revenue & Profitability Trend
Xenon Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 9.4M | 18.4M | 32.2M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 279.3M | 214.1M | 138.6M | 97.4M | 63.5M |
| Operating Income | -279.3M | -214.1M | -129.1M | -79.0M | -31.3M |
| Pre-tax Income | -238.4M | -182.7M | -125.3M | -78.9M | -29.1M |
| Income Tax | -4.1M | -292.0K | 118.0K | -6.0K | -257.0K |
| Net Income | -234.3M | -182.4M | -125.4M | -78.9M | -28.8M |
| EPS (Diluted) | - | -$2.73 | -$2.06 | -$1.77 | -$0.81 |
Income Statement Trend
Xenon Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 635.3M | 645.0M | 600.3M | 559.0M | 181.8M |
| Non-Current Assets | 162.9M | 319.8M | 153.8M | 13.0M | 7.4M |
| Total Assets | 798.1M | 964.8M | 754.1M | 572.0M | 189.2M |
| Liabilities | |||||
| Current Liabilities | 35.6M | 27.3M | 22.7M | 14.3M | 14.8M |
| Non-Current Liabilities | 7.6M | 9.6M | 9.9M | 7.7M | 3.0M |
| Total Liabilities | 43.2M | 36.9M | 32.6M | 22.0M | 17.8M |
| Equity | |||||
| Total Shareholders Equity | 754.9M | 927.9M | 721.5M | 550.0M | 171.4M |
Balance Sheet Composition
Xenon Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -234.3M | -182.4M | -125.4M | -78.9M | -28.8M |
| Operating Cash Flow | -190.5M | -146.6M | -101.7M | -72.0M | -50.4M |
| Investing Activities | |||||
| Capital Expenditures | -3.1M | -5.6M | -2.9M | -2.0M | -2.6M |
| Investing Cash Flow | 165.0M | -117.2M | -296.0M | -246.8M | -16.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 12.1M | 353.5M | 277.8M | 447.3M | 85.7M |
| Free Cash Flow | -184.5M | -150.9M | -101.3M | -71.6M | -50.8M |
Cash Flow Trend
Xenon Key Financial Ratios
Valuation Ratios
Forward P/E
-8.95
Price to Book
3.47
Price to Sales
326.07
PEG Ratio
-8.95
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-969.84%
Return on Equity
-31.60%
Return on Assets
-22.03%
Financial Health
Current Ratio
17.66
Debt to Equity
1.23
Beta
1.10
Per Share Data
EPS (TTM)
-$3.22
Book Value per Share
$9.19
Revenue per Share
$0.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| xene | 2.4B | - | 3.47 | -31.60% | 0.00% | 1.23 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.14 | 24.23 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.